Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC6280 | SA 57 |
| Potent inhibitor of fatty acid amide hydrolase (FAAH) (IC50 <10 nM). Also inhibits MAGL at higher concentrations (IC50 values are 410 nM and 1.4 μM respectively). Inhibits both human and mouse FAAH enzymes. Exhibits inhibitory activity against FAAH, MAGL and ABHD6 in vivo. | |
| BCC6281 | Q94 hydrochloride |
| PAR1 negative allosteric modulator (IC50 = 916 nM); inhibits PAR1-Gαq interaction. Selective for PAR1 over PAR2. Blocks thrombin-induced intracellular calcium mobilization (IC50 = 10.3 nM), CCL2 expression, ERK1/2 and MLC phosphorylation, and IP3 production in cells. | |
| BCC6283 | G-36 |
| Antagonist of GPER; selectively inhibits estrogen-mediated activation of PI3-K by GPER, but not by ERα. Also inhibits estrogen-mediated calcium mobilization (IC50 = 112 nM). Structural analog of G-1. | |
| BCC6284 | SIB 1553A hydrochloride |
| Nicotinic acetylcholine receptor (nAChR) agonist. Displays selectivity for β4 subunit-containing receptors. Stimulates acetylcholine levels and other neurotransmitters relevant for cognitive processes. Improves attention deficits and memory performance in a Parkinson's disease model. | |
| BCC6287 | ANA 12 |
| TrkB receptor antagonist. Demonstrates a 2-site mode of action, preventing activation by BDNF non-competitively (IC50 values are 45.6 nM and 41.1 μM for the high and low affinity sites respectively). Displays no effect on TrkA and TrkC in an assay of neurite outgrowth. Demonstrates antidepressant properties. | |
| BCC6288 | Org 25543 hydrochloride |
| Potent and selective glycine transporter type 2 (GlyT2) inhibitor (IC50 = 16 nM for hGlyT2). Displays no activity at GlyT1 or 56 other common biological targets (≥ 100 μM), in a glycine uptake assay in CHO cells. Ameliorates mechanical allodynia after partial sciatic nerve ligation injury in mice. | |
| BCC6292 | QNZ 46 |
| NR2C/NR2D-selective NMDA receptor non-competitive antagonist (IC50 values are 3, 6, 229, and >300, >300 μM for NR2D, NR2C, NR2A, NR2B, and GluR1, respectively). Requires binding of glutamate to the GluN2 subunit. | |
| BCC6293 | CRANAD 2 |
| Near-infrared probe that binds to Aβ40 aggregates (Kd = 38 nM) and elicits an emission blue shift. Shown to bind to plaques in APP-PS1 transgenic mice, in vitro. Detects senile plaques in 19-month-old Tg2576 mice in vivo. Penetrates the blood-brain barrier. | |
